Ozmosi | Suvecaltamide Drug Profile

Product Description

Suvecaltamide (also known as JZP385) is a highly selective modulator of T-type calcium channels in development for the potential treatment of moderate to severe essential tremor (ET). T-type calcium channels play a role in the brain's management of muscle movement. (Sourced from: http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-first-patient-enrolled-phase-2b)

Mechanisms of Action: T-Type Calcium Channel

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Jazz
Company Location: Europe
Company Founding Year: 2003
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Suvecaltamide

Countries in Clinic: Germany, Poland, Spain, United States

Active Clinical Trial Count: 4

Recent & Upcoming Milestones

Clinical Outcomes Reported - Jazz presented P2 Essential Tremor|Tremor results on 2024-06-20 for Suvecaltamide
Clinical Outcomes Reported - Jazz announced they will present P2 Essential Tremor|Tremor results in 1H24 for Suvecaltamide
Clinical Outcomes Reported - Jazz presented P2 Parkinson's Disease|Tremor results on 2024-04-17 for Suvecaltamide

Highest Development Phases

Phase 2: Essential Tremor|Parkinson's Disease|Tremor

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT05642442	JZP385-202	P2	Completed	Parkinson's Disease\|Tremor	2024-10-23	2025-01-30	Primary Completion Date\|Primary Endpoints
NCT05122650	JZP385-201	P2	Completed	Essential Tremor	2024-05-30	2024-07-31	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
2024-515177-94-00	JZP385-202-01	P2	Completed	Parkinson's Disease	2024-11-01	2025-05-02	Treatments
2020-002463-61	2020-002463-61	P2	Completed	Essential Tremor	2024-05-30	2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status

Recent News Events

Date	Type	Title
06/20/2024	News Article	Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
04/10/2024	News Article	Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
09/15/2023	News Article	This report projects that the global Childhood Absence Epilepsy Treatment market will grow at a CAGR of 8.6% during the 2023 to 2030 period
01/16/2023	News Article	Epilepsy Monitoring Devices Market Size to Surpass USD 1,510.51 Million by 2030, Share, Growth, Demand, Global Trends, Segmentation and Competitive Outlook

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Suvecaltamide

Alternative Names: Suvecaltamide, jzp-385, jzp 385, jzp385, cx-8998, cx8998, cx 8998, mk-8998, mk8998, mk 8998 Clinical Status: Active Latest Update: 2025-01-28 Latest Update Note: Clinical Trial Update